Catalog No.
RHJ15602
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Monoclonal
Tested applications
FCM: 1:20-1:100, IF: 1:50-1:200, IHC: 1:100-1:200, WB: 1:1000-1:2000
Target
PBRM1, Polybromo-1D, hPB1, Protein polybromo-1, BAF180, BRG1-associated factor 180, PB1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q86U86
Applications
FCM, IF, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.
Clone ID
R2H99
Prognostic impact and landscape of cellular CXCR5 chemokine receptor expression in clear-cell renal cell carcinoma., PMID:40208344
PBRM1 deficiency enhances PD1 immunotherapeutic sensitivity via chromosomal accessibility in colorectal cancer., PMID:40093909
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma., PMID:39910301
The value of serum tumor-associated autoantibodies in screening and diagnosis of gastric cancer., PMID:39900126
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma., PMID:39672382
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation., PMID:39218995
Durable radiologic and molecular complete response following nivolumab in an HNSCC patient with UV signature and HIV., PMID:38781626
Clinical Implications of a Six-Protein Signature in Bone Metastasis of Renal Cell Carcinoma., PMID:38706914
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol., PMID:38630551
PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study., PMID:38048211
An Overview of Renal Cell Carcinoma Hallmarks, Drug Resistance, and Adjuvant Therapies., PMID:37927802
Interrogating the Significance of PARP1 Expression and PBRM1 Mutation as Biomarkers for Predicting the Response to Atezolizumab plus Bevacizumab or to Sunitinib in Patients with Clear Cell Renal Cell Carcinoma., PMID:35688666
Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101., PMID:35397432
The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma., PMID:34627641
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study., PMID:34491815
Durable Response to Immunotherapy With Antiangiogenic Drug in Large-Cell Lung Carcinoma With Multiple Fulminant Postoperative Metastases: A Case Report., PMID:34094914
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial., PMID:33412465
Discovery and Validation of Serum Autoantibodies Against Tumor-Associated Antigens as Biomarkers in Gastric Adenocarcinoma Based on the Focused Protein Arrays., PMID:33346593
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade., PMID:33157048
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial., PMID:32673417
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial., PMID:32661118
Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective., PMID:32630154
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma., PMID:32472114
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma., PMID:32358509
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma., PMID:32339648
Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma., PMID:32293336
Comparative genomic profiling of glandular bladder tumours., PMID:32198650
Complete and Prolonged Response of Renal Cell Carcinoma With Rhabdoid Features to Checkpoint Inhibitor Therapy., PMID:29965859
SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients., PMID:29689242
Molecular hypotheses to explain the shared pathways and underlying pathobiological causes in catatonia and in catatonic presentations in neuropsychiatric disorders., PMID:29523295
A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma., PMID:27727447
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy., PMID:27664394
The clinical significance of SWI/SNF complex in pancreatic cancer., PMID:23229642
The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer., PMID:15735765
Molecular cloning of polybromo, a nuclear protein containing multiple domains including five bromodomains, a truncated HMG-box, and two repeats of a novel domain., PMID:8917104
For research use only. Not for human or drug use.
